Last updated: June 11, 2026
LIPOFEN (fenofibrate) Clinical Trials Update, Market Analysis, and Projection: IP, Generics Risk, and Revenue Outlook
What is LIPOFEN and which fenofibrate product does it correspond to
Quick answer: LIPOFEN is a fenofibrate brand used for hyperlipidemia management. Market exposure depends on whether the product is the specific FDA-approved fenofibrate formulation under the LIPOFEN trade name and its dosage strength (mg) and route (oral). Fenofibrate is also marketed under multiple brands globally and as generics in the US and internationally.
Drug class and therapeutic use
- Active ingredient: fenofibrate
- Class: fibric acid derivative (PPAR-alpha agonist)
- Indications generally include:
- Hypertriglyceridemia (to reduce triglycerides)
- Mixed dyslipidemia (as monotherapy or adjunct)
- Other lipid-related uses based on the approved labeling for the specific version of the product
What drives utilization
- Triglyceride severity distribution in patient populations
- Statin intolerance or insufficient response to statins
- Prescriber switching between fenofibrate brands and generics
- Payer formularies and step edits
- Safety monitoring requirements (notably renal function and muscle-related events)
What clinical trials data support Lipofen (fenofibrate) and what is the current update
Quick answer: For fenofibrate, the core efficacy and safety evidence base is anchored in older randomized trials and meta-analyses. Current “clinical trials updates” tend to center on real-world evidence, label updates, pharmacovigilance, comparative effectiveness, and new formulation or bioequivalence rather than new Phase 3 outcomes that restart exclusivity.
How the clinical evidence typically updates for fenofibrate brands
-
Real-world comparative effectiveness
- Switching among fenofibrate formulations and brands versus generics
- Persistence and adherence patterns
- Safety outcomes in routine practice
-
Pharmacokinetics and formulation work
- Bioequivalence studies for generic or authorized alternatives
- Dose-normalized exposure comparisons across fenofibrate formulations
-
Safety surveillance
- Post-marketing reports for hepatic and renal parameters
- Monitoring protocols and risk communication updates
What matters for market projection
- Any new label expansions or restriction changes for LIPOFEN specifically
- Safety signals that shift prescribing behavior away from fenofibrate
- Generic competition intensity in the relevant dose forms
What patents protect LIPOFEN (fenofibrate) and how many are still active
Critical point: Patent protection for fenofibrate products in the US typically expired decades after first filing, with many remaining patents related to specific formulations, metabolites, manufacturing methods, or polymorphs, depending on the specific formulation tied to the LIPOFEN NDA/ANDA.
Patent estate structure that usually governs fenofibrate brands
- Compound patents: usually expired
- Formulation patents: can be shorter-lived depending on when the branded formulation was introduced
- Method-of-use patents: rarely renewed for core lipid endpoints for older agents
- Orange Book-listed patents (if any): often limited and nearing expiry
IP implication for projection
- If no active Orange Book-listed exclusivities/patents remain for the specific LIPOFEN NDA, generic erosion will dominate volume and price.
- If formulation patents remain, expect delayed generic entry or “authorized generic” or “carve-out” market access strategies.
(No Orange Book listing details, patent numbers, or NDA/label-specific mappings were provided in the prompt, so a definitive patent-by-patent table cannot be produced without inventing data.)
When does LIPOFEN lose exclusivity and when do generics enter risk-free
Quick answer: Fenofibrate as a molecule is largely generic. Market access risk for LIPOFEN is therefore driven less by molecule-level exclusivity and more by whether the specific LIPOFEN formulation has Orange Book-listed patents or periods of pediatric exclusivity, exclusivity tied to a specific NDA supplement, or other time-limited protections.
Exclusivity vectors that can still matter even with older drugs
- Patent expiry on formulation or manufacturing claims
- NDA exclusivity tied to a particular formulation change
- 505(b)(2)-linked exclusivity (if applicable)
- Exclusivity triggered by labeling changes (rare for mature agents)
What typically happens in practice
- Once the specific formulation is no longer protected, generics expand quickly after ANDA approval or under Paragraph IV challenges (if there is remaining patent coverage).
What is the Orange Book status of LIPOFEN and what patents are listed
Quick answer: The Orange Book status is product-specific: it requires the exact LIPOFEN NDA (and strength/dosage form mapping). Without an NDA/ANDA identifier in the prompt, a correct Orange Book inventory cannot be generated.
What you would normally extract
- Listed patents and their expiration dates
- Patent types (drug substance, drug product, method of use)
- Exclusivity codes (if any)
- Orange Book “listed” versus “approved” discrepancy
What generic entry risks exist for LIPOFEN and how do they play out (Paragraph IV, settlement, authorized generics)
Quick answer: For mature fenofibrate brands, generic entry is usually inevitable once formulation patents and exclusivities end. The practical risk is speed and scope of generic uptake, not whether entry is possible.
Typical pathways affecting market penetration
- ANDA approval after expiry without Paragraph IV litigation (fastest)
- Paragraph IV (if patents remain) leading to:
- 180-day exclusivity triggers
- Settlement agreements limiting entry dates for other filers
- Authorized generics launched by brand sponsors post-settlement or via licensing
How this affects pricing and revenue
- Generic entry compresses net price and increases rebates.
- The brand often shifts to a “defend-specific-strength” model only if there are residual product-protection barriers.
How does LIPOFEN compete with other fenofibrate brands and generic fenofibrate
Quick answer: Competition is primarily with:
- Other branded fenofibrate products (depending on geography)
- Low-priced generics with high formulary penetration
Competitive dynamics to project
- Net revenue tends to be driven by:
- Market share retention versus brand switching
- Pharmacy channel inventory and rebate structures
- State Medicaid and large PBM formularies
What determines “outperformance” versus “slope down”
- Differences in dosing convenience or pill burden (if any for the specific LIPOFEN formulation)
- Label positioning that supports higher utilization in dyslipidemia subsegments
- Payer coverage breadth for the LIPOFEN brand versus generics
What is the FDA regulatory status of LIPOFEN (NDA, ANDA relationship, labeling, pathway)
Quick answer: Fenofibrate brands typically rely on legacy approvals, with generic pathways governed by ANDA. But the regulatory status of LIPOFEN must be confirmed against the specific NDA record.
What to measure for a market forecast
- Whether new approvals or labeling updates occurred recently
- Whether any FDA safety communications changed risk-benefit positioning
- Whether generics are already approved and launched in the relevant strengths
Market analysis: current sales base, pricing pressure, and demand drivers
Quick answer: Fenofibrate demand is mature and highly genericized. Market projections for LIPOFEN are typically characterized by:
- Volume instability around generic launches
- Sustained price compression after entry
- Stable underlying chronic-disease demand
Demand drivers
- Patient population with persistent hypertriglyceridemia
- Clinician preference and familiarity
- Treatment guidelines emphasis and payer coverage policies
Supply and channel structure
- Generic density across strengths
- Multiple-generic competition reduces price and increases rebate pressure
- PBM formulary placement is decisive
(No unit sales, revenue figures, or market share baselines for LIPOFEN were included in the prompt, so a quantified market table cannot be produced without fabricating numbers.)
Revenue projection for LIPOFEN: base case, downside, and upside scenarios
Quick answer: For mature fenofibrate brands, three factors dominate projection:
- Timing and intensity of generic penetration for the specific LIPOFEN formulation
- Strength-specific prescribing behavior and formulary status
- Ongoing discounting and rebate pressure
Projection framework (scenario mechanics)
- Base case: slow erosion driven by continued generic substitution; revenue declines at a rate reflecting net price compression and modest volume share loss.
- Downside: accelerated share loss from additional competitors, stronger PBM rebate pressure, or wider generic formulary switches.
- Upside: delayed generic uptake due to residual formulation protections, preferred status in certain plans, or lower competitive density.
(Because no LIPOFEN-specific timeline of generic launches, Orange Book patent expiries, or current sales baseline is provided, scenario numerics cannot be computed accurately.)
Which companies are challenging LIPOFEN with generics and where are they positioned
Quick answer: Generic challengers for mature fenofibrate formulations are typically large ANDA filers and established generic manufacturers. But without the LIPOFEN NDA identifier, ANDA/Paragraph IV filings cannot be enumerated correctly.
What would normally be documented
- ANDA applicants
- Filing dates and patent lists used for Paragraph IV
- Litigation docket outcomes and settlement terms
- Earliest commercial launch dates per strength
What patent litigation affects LIPOFEN and does it change launch timing
Quick answer: Patent litigation for fenofibrate brands occurs mainly when formulation or method-of-use patents are still asserted. For LIPOFEN, litigation impact is only forecastable with confirmed Orange Book patents and actual case records.
Litigation outcomes that matter
- Court rulings on patent validity/infringement
- Settlement agreements limiting “skinny” vs full label entry
- Carve-outs for specific dosage strengths
- Shared 180-day exclusivity triggers
Key takeaways
- LIPOFEN is a fenofibrate brand in a class that is largely genericized in most major markets; business impact is driven by formulation-specific remaining IP, not compound-level protection.
- A definitive LIPOFEN exclusivity and patent-loss timeline requires the exact FDA NDA mapping and Orange Book listing; without that, a correct patent-by-patent assessment cannot be produced.
- Revenue projection should be built on formulation-specific generic entry timing, net price compression mechanics, and formulary penetration rather than on new clinical trial efficacy endpoints.
FAQs
- How do I determine the exact NDA/strength mapping for “LIPOFEN” when building an exclusivity and generic entry timeline?
- What is the fastest generic entry pathway for mature fenofibrate brands once formulation patents expire?
- How do Orange Book patent “types” (drug product vs method of use) change the litigation and settlement risk profile for fenofibrate formulations?
- What are the most common drivers of net price erosion for older lipid agents after generic launches?
- How do safety monitoring and risk communications influence fenofibrate prescribing trends in real-world practice?
References
(No sources were provided in the prompt, and no verified Orange Book, FDA, or clinical-trial registry identifiers for “LIPOFEN” were included. No references can be listed without risking fabrication.)
